The U.S. Food and Drug Administration is recalling 89,312 bottles of NasoGel nasal spray because the product might cause ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...

There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...